ATHE and ATH Related Headlines
Go Back- Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics receives FDA alignment on ATH434 manufacturing plans
- Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
- Alterity Therapeutics shares new ATH434 trial data at neurology meeting
- Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
- Alterity Therapeutics appoints Ann Cunningham to board of directors
- Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
- Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
- Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
ATHE and ATH Related Press Releases
Go Back- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
- Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
- Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
- Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
- Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
